NUCLEUS-SOFTWARE
5.10.2021 15:09:13 CEST | Business Wire | Press release
Opel Vauxhall Finance announces the going live in Spain of Nucleus Software’s flagship lending product, FinnOne. Nucleus Software is the leading provider of lending and transaction banking products and solutions to the global financial industry. Spain becomes the ninth European country for Opel Vauxhall Finance (OVF) to go live with FinnOne.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005757/en/
OVF is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution.
While FinnOne has been supporting businesses for Opel Vauxhall Finance in Europe since 2006, Spain is the latest country that will run OVF business using FinnOne. The OVF FinnOne partnership began in Italy and then moved on to Belgium, Netherlands, UK, France, Germany, Austria and Switzerland. The OVF portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts.
Opel Vauxhall Finance wanted to utilize its core applications to achieve economies of scale. Nucleus Software FinnOne SRS (Strategic Retail Solution) is helping OVF in leveraging existing functionalities and aligning Spanish business processes to the OVF strategic applications rather than customizing and increasing scope & cost.
“With FinnOne going live in Spain, Opel Vauxhall Finance will be able to improve operational efficiency and align with the corporate strategic technology framework. With enhanced digitization, we will also be able to strengthen the collaboration framework with Opel/Vauxhall to increase the volume of financed/leased vehicles while at the same time raising retail margins across Europe,” says Alexandre Sorel, CEO of Opel Vauxhall Finance.
“We are proud to continue to bring value to our long-term partnership with Opel Vauxhall Finance (OVF). Spain is the ninth European country where FinnOne is supporting OVF in running their complex business. Having a common solution running across nine countries provides a competitive edge to OVF in terms of operational efficiency, uniform rollouts and standardization. We were able to go live despite the pandemic by meeting business commitments thanks to the coming together of OVF and Nucleus teams using our deep expertise in off-shore implementation methodology,” says Parag Bhise, CEO, Nucleus Software.
About Opel Vauxhall Finance:
OVF (Opel Vauxhall Finance) is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas, taken over from GM Financial in 2017. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution. For IT Operations, everything is controlled from UK under the name Opel Vauxhall Finance.
Its portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts as well as dealer financing. In Germany, OVF also offer money market accounts and fixed-term deposits directly to end-consumers, complementing our traditional automotive finance business.
OVF's primary goal is to meet the mobility needs of customers across Europe, while sustaining and developing the Opel and Vauxhall brands through competitive and attractive automotive finance solutions. Financing Opel and Vauxhall Brands dates back to 1920 when it opened its first office in London, helping people in the UK to finance their vehicles. In 1929 Opel Finanzierungsgesellschaft mbH was founded in Russelsheim, Germany, as the strategic finance partner for Opel.
About Nucleus Software:
Nucleus Software Exports Ltd. is a publicly traded (BSE: 531209, NSE: NUCLEUS) software product company that provides lending and transaction banking products to global financial leaders.
Nucleus Software powers the operations of more than 200 Financial Institutions in over 50 countries, supporting retail lending, corporate banking, cash management, mobile and internet banking, automotive finance and other business areas. Its products facilitate more than 26 million transactions each day, managing over US $200 billion of loans and enabling more than 200,000 users logging in daily.
For more information, please visit: www.nucleussoftware.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005757/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom